Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 1926 entries
Sorted by: Best Match Show Resources per page
Preclinical and translational evaluation of coagulation factor IXa as a novel therapeutic target.

Pharmacology research & perspectives

Ankrom W, Wood HB, Xu J, Geissler W, Bateman T, Chatterjee MS, Feng KI, Metzger JM, Strapps WR, Tadin-Strapps M, Seiffert D, Andre P.
PMID: 26977298
Pharmacol Res Perspect. 2016 Jan 15;4(1):e00207. doi: 10.1002/prp2.207. eCollection 2016 Feb.

The benefits of novel oral anticoagulants are hampered by bleeding. Since coagulation factor IX (fIX) lies upstream of fX in the coagulation cascade, and intermediate levels have been associated with reduced incidence of thrombotic events, we evaluated the viability...

Cite
Ankrom W, Wood HB, Xu J, et al. Preclinical and translational evaluation of coagulation factor IXa as a novel therapeutic target. Pharmacol Res Perspect. 2016;4(1):e00207doi: 10.1002/prp2.207.
Ankrom, W., Wood, H. B., Xu, J., Geissler, W., Bateman, T., Chatterjee, M. S., Feng, K. I., Metzger, J. M., Strapps, W. R., Tadin-Strapps, M., Seiffert, D., & Andre, P. (2016). Preclinical and translational evaluation of coagulation factor IXa as a novel therapeutic target. Pharmacology research & perspectives, 4(1), e00207. https://doi.org/10.1002/prp2.207
Ankrom, Wendy, et al. "Preclinical and translational evaluation of coagulation factor IXa as a novel therapeutic target." Pharmacology research & perspectives vol. 4,1 (2016): e00207. doi: https://doi.org/10.1002/prp2.207
Ankrom W, Wood HB, Xu J, Geissler W, Bateman T, Chatterjee MS, Feng KI, Metzger JM, Strapps WR, Tadin-Strapps M, Seiffert D, Andre P. Preclinical and translational evaluation of coagulation factor IXa as a novel therapeutic target. Pharmacol Res Perspect. 2016 Jan 15;4(1):e00207. doi: 10.1002/prp2.207. eCollection 2016 Feb. PMID: 26977298; PMCID: PMC4777260.
Copy Download .nbib Format: NLM
Antidepressant activity of fingolimod in mice.

Pharmacology research & perspectives

di Nuzzo L, Orlando R, Tognoli C, Di Pietro P, Bertini G, Miele J, Bucci D, Motolese M, Scaccianoce S, Caruso A, Mauro G, De Lucia C, Battaglia G, Bruno V, Fabene PF, Nicoletti F.
PMID: 26171219
Pharmacol Res Perspect. 2015 Jun;3(3):e00135. doi: 10.1002/prp2.135. Epub 2015 May 24.

Recent findings indicate that fingolimod, the first oral drug approved for the treatment of multiple sclerosis (MS), acts as a direct inhibitor of histone deacetylases (HDACs) and enhances the production of brain-derived neurotrophic factor (BDNF) in the CNS. Both...

Cite
di Nuzzo L, Orlando R, Tognoli C, et al. Antidepressant activity of fingolimod in mice. Pharmacol Res Perspect. 2015;3(3):e00135doi: 10.1002/prp2.135.
di Nuzzo, L., Orlando, R., Tognoli, C., Di Pietro, P., Bertini, G., Miele, J., Bucci, D., Motolese, M., Scaccianoce, S., Caruso, A., Mauro, G., De Lucia, C., Battaglia, G., Bruno, V., Fabene, P. F., & Nicoletti, F. (2015). Antidepressant activity of fingolimod in mice. Pharmacology research & perspectives, 3(3), e00135. https://doi.org/10.1002/prp2.135
di Nuzzo, Luigi, et al. "Antidepressant activity of fingolimod in mice." Pharmacology research & perspectives vol. 3,3 (2015): e00135. doi: https://doi.org/10.1002/prp2.135
di Nuzzo L, Orlando R, Tognoli C, Di Pietro P, Bertini G, Miele J, Bucci D, Motolese M, Scaccianoce S, Caruso A, Mauro G, De Lucia C, Battaglia G, Bruno V, Fabene PF, Nicoletti F. Antidepressant activity of fingolimod in mice. Pharmacol Res Perspect. 2015 Jun;3(3):e00135. doi: 10.1002/prp2.135. Epub 2015 May 24. PMID: 26171219; PMCID: PMC4492751.
Copy Download .nbib Format: NLM
The putative P-gp inhibitor telmisartan does not affect the transcellular permeability and cellular uptake of the calcium channel antagonist verapamil in the P-glycoprotein expressing cell line MDCK II MDR1.

Pharmacology research & perspectives

Saaby L, Tfelt-Hansen P, Brodin B.
PMID: 26171231
Pharmacol Res Perspect. 2015 Aug;3(4):e00151. doi: 10.1002/prp2.151. Epub 2015 Jun 11.

Verapamil is used in high doses for the treatment of cluster headache. Verapamil has been described as a P-glycoprotein (P-gp, ABCB1) substrate. We wished to evaluate in vitro whether co administration of a P-gp inhibitor with verapamil could be...

Cite
Saaby L, Tfelt-Hansen P, Brodin B. The putative P-gp inhibitor telmisartan does not affect the transcellular permeability and cellular uptake of the calcium channel antagonist verapamil in the P-glycoprotein expressing cell line MDCK II MDR1. Pharmacol Res Perspect. 2015;3(4):e00151doi: 10.1002/prp2.151.
Saaby, L., Tfelt-Hansen, P., & Brodin, B. (2015). The putative P-gp inhibitor telmisartan does not affect the transcellular permeability and cellular uptake of the calcium channel antagonist verapamil in the P-glycoprotein expressing cell line MDCK II MDR1. Pharmacology research & perspectives, 3(4), e00151. https://doi.org/10.1002/prp2.151
Saaby, Lasse, et al. "The putative P-gp inhibitor telmisartan does not affect the transcellular permeability and cellular uptake of the calcium channel antagonist verapamil in the P-glycoprotein expressing cell line MDCK II MDR1." Pharmacology research & perspectives vol. 3,4 (2015): e00151. doi: https://doi.org/10.1002/prp2.151
Saaby L, Tfelt-Hansen P, Brodin B. The putative P-gp inhibitor telmisartan does not affect the transcellular permeability and cellular uptake of the calcium channel antagonist verapamil in the P-glycoprotein expressing cell line MDCK II MDR1. Pharmacol Res Perspect. 2015 Aug;3(4):e00151. doi: 10.1002/prp2.151. Epub 2015 Jun 11. PMID: 26171231; PMCID: PMC4492727.
Copy Download .nbib Format: NLM
Increased efficacy of VX-809 in different cellular systems results from an early stabilization effect of F508del-CFTR.

Pharmacology research & perspectives

Farinha CM, Sousa M, Canato S, Schmidt A, Uliyakina I, Amaral MD.
PMID: 26171232
Pharmacol Res Perspect. 2015 Aug;3(4):e00152. doi: 10.1002/prp2.152. Epub 2015 Jun 11.

Cystic fibrosis (CF), the most common recessive autosomal disease among Caucasians, is caused by mutations in the gene encoding the CF transmembrane conductance regulator (CFTR) protein. The most common mutation, F508del, leads to CFTR impaired plasma membrane trafficking. Therapies...

Cite
Farinha CM, Sousa M, Canato S, et al. Increased efficacy of VX-809 in different cellular systems results from an early stabilization effect of F508del-CFTR. Pharmacol Res Perspect. 2015;3(4):e00152doi: 10.1002/prp2.152.
Farinha, C. M., Sousa, M., Canato, S., Schmidt, A., Uliyakina, I., & Amaral, M. D. (2015). Increased efficacy of VX-809 in different cellular systems results from an early stabilization effect of F508del-CFTR. Pharmacology research & perspectives, 3(4), e00152. https://doi.org/10.1002/prp2.152
Farinha, Carlos M, et al. "Increased efficacy of VX-809 in different cellular systems results from an early stabilization effect of F508del-CFTR." Pharmacology research & perspectives vol. 3,4 (2015): e00152. doi: https://doi.org/10.1002/prp2.152
Farinha CM, Sousa M, Canato S, Schmidt A, Uliyakina I, Amaral MD. Increased efficacy of VX-809 in different cellular systems results from an early stabilization effect of F508del-CFTR. Pharmacol Res Perspect. 2015 Aug;3(4):e00152. doi: 10.1002/prp2.152. Epub 2015 Jun 11. PMID: 26171232; PMCID: PMC4492728.
Copy Download .nbib Format: NLM
Efficacy of tomato concentrates in mouse models of dyslipidemia and cancer.

Pharmacology research & perspectives

Chattopadhyay A, Grijalva V, Hough G, Su F, Mukherjee P, Farias-Eisner R, Anantharamaiah GM, Faull KF, Hwang LH, Navab M, Fogelman AM, Reddy ST.
PMID: 26171234
Pharmacol Res Perspect. 2015 Aug;3(4):e00154. doi: 10.1002/prp2.154. Epub 2015 Jun 24.

We previously reported that adding freeze-dried tomato powder from transgenic plants expressing the apolipoprotein A-I mimetic peptide 6F at 2.2% by weight to a Western diet (WD) ameliorated dyslipidemia and atherosclerosis in mice. The same dose in a human...

Cite
Chattopadhyay A, Grijalva V, Hough G, et al. Efficacy of tomato concentrates in mouse models of dyslipidemia and cancer. Pharmacol Res Perspect. 2015;3(4):e00154doi: 10.1002/prp2.154.
Chattopadhyay, A., Grijalva, V., Hough, G., Su, F., Mukherjee, P., Farias-Eisner, R., Anantharamaiah, G. M., Faull, K. F., Hwang, L. H., Navab, M., Fogelman, A. M., & Reddy, S. T. (2015). Efficacy of tomato concentrates in mouse models of dyslipidemia and cancer. Pharmacology research & perspectives, 3(4), e00154. https://doi.org/10.1002/prp2.154
Chattopadhyay, Arnab, et al. "Efficacy of tomato concentrates in mouse models of dyslipidemia and cancer." Pharmacology research & perspectives vol. 3,4 (2015): e00154. doi: https://doi.org/10.1002/prp2.154
Chattopadhyay A, Grijalva V, Hough G, Su F, Mukherjee P, Farias-Eisner R, Anantharamaiah GM, Faull KF, Hwang LH, Navab M, Fogelman AM, Reddy ST. Efficacy of tomato concentrates in mouse models of dyslipidemia and cancer. Pharmacol Res Perspect. 2015 Aug;3(4):e00154. doi: 10.1002/prp2.154. Epub 2015 Jun 24. PMID: 26171234; PMCID: PMC4492730.
Copy Download .nbib Format: NLM
Diclofenac, a nonsteroidal anti-inflammatory drug, is an antagonist of human TRPM3 isoforms.

Pharmacology research & perspectives

Suzuki H, Sasaki E, Nakagawa A, Muraki Y, Hatano N, Muraki K.
PMID: 27433342
Pharmacol Res Perspect. 2016 Apr 07;4(3):e00232. doi: 10.1002/prp2.232. eCollection 2016 Jun.

The effects of diclofenac (Dic), an acetic acid derivative-type nonsteroidal anti-inflammatory drug, were examined on the function of transient receptor potential (TRP) melastatin (TRPM) 3 (TRPM3) in human embryonic kidney 293 cell-line (HEK293) cells with recombinant human TRPM3 isoforms...

Cite
Suzuki H, Sasaki E, Nakagawa A, et al. Diclofenac, a nonsteroidal anti-inflammatory drug, is an antagonist of human TRPM3 isoforms. Pharmacol Res Perspect. 2016;4(3):e00232doi: 10.1002/prp2.232.
Suzuki, H., Sasaki, E., Nakagawa, A., Muraki, Y., Hatano, N., & Muraki, K. (2016). Diclofenac, a nonsteroidal anti-inflammatory drug, is an antagonist of human TRPM3 isoforms. Pharmacology research & perspectives, 4(3), e00232. https://doi.org/10.1002/prp2.232
Suzuki, Hiroka, et al. "Diclofenac, a nonsteroidal anti-inflammatory drug, is an antagonist of human TRPM3 isoforms." Pharmacology research & perspectives vol. 4,3 (2016): e00232. doi: https://doi.org/10.1002/prp2.232
Suzuki H, Sasaki E, Nakagawa A, Muraki Y, Hatano N, Muraki K. Diclofenac, a nonsteroidal anti-inflammatory drug, is an antagonist of human TRPM3 isoforms. Pharmacol Res Perspect. 2016 Apr 07;4(3):e00232. doi: 10.1002/prp2.232. eCollection 2016 Jun. PMID: 27433342; PMCID: PMC4876142.
Copy Download .nbib Format: NLM
A phase 1 study comparing the proposed biosimilar BS-503a with bevacizumab in healthy male volunteers.

Pharmacology research & perspectives

Tajima N, Martinez A, Kobayashi F, He L, Dewland P.
PMID: 28357118
Pharmacol Res Perspect. 2017 Feb 20;5(2):e00286. doi: 10.1002/prp2.286. eCollection 2017 Apr.

This is a randomized, double-blind, single-dose, parallel group phase 1 study to assess pharmacokinetic similarity, safety, and tolerability of BS-503a, a proposed bevacizumab biosimilar. A total of 114 male healthy subjects were randomized (1:1) to receive a single 3...

Cite
Tajima N, Martinez A, Kobayashi F, et al. A phase 1 study comparing the proposed biosimilar BS-503a with bevacizumab in healthy male volunteers. Pharmacol Res Perspect. 2017;5(2):e00286doi: 10.1002/prp2.286.
Tajima, N., Martinez, A., Kobayashi, F., He, L., & Dewland, P. (2017). A phase 1 study comparing the proposed biosimilar BS-503a with bevacizumab in healthy male volunteers. Pharmacology research & perspectives, 5(2), e00286. https://doi.org/10.1002/prp2.286
Tajima, Naoyuki, et al. "A phase 1 study comparing the proposed biosimilar BS-503a with bevacizumab in healthy male volunteers." Pharmacology research & perspectives vol. 5,2 (2017): e00286. doi: https://doi.org/10.1002/prp2.286
Tajima N, Martinez A, Kobayashi F, He L, Dewland P. A phase 1 study comparing the proposed biosimilar BS-503a with bevacizumab in healthy male volunteers. Pharmacol Res Perspect. 2017 Feb 20;5(2):e00286. doi: 10.1002/prp2.286. eCollection 2017 Apr. PMID: 28357118; PMCID: PMC5368956.
Copy Download .nbib Format: NLM
Metabolic effects of a mitochondrial-targeted coenzyme Q analog in high fat fed obese mice.

Pharmacology research & perspectives

Fink BD, Guo DF, Kulkarni CA, Rahmouni K, Kerns RJ, Sivitz WI.
PMID: 28357127
Pharmacol Res Perspect. 2017 Mar 10;5(2):e00301. doi: 10.1002/prp2.301. eCollection 2017 Apr.

We recently reported that mitoquinone (mitoQ, 500 

Cite
Fink BD, Guo DF, Kulkarni CA, et al. Metabolic effects of a mitochondrial-targeted coenzyme Q analog in high fat fed obese mice. Pharmacol Res Perspect. 2017;5(2):e00301doi: 10.1002/prp2.301.
Fink, B. D., Guo, D. F., Kulkarni, C. A., Rahmouni, K., Kerns, R. J., & Sivitz, W. I. (2017). Metabolic effects of a mitochondrial-targeted coenzyme Q analog in high fat fed obese mice. Pharmacology research & perspectives, 5(2), e00301. https://doi.org/10.1002/prp2.301
Fink, Brian D, et al. "Metabolic effects of a mitochondrial-targeted coenzyme Q analog in high fat fed obese mice." Pharmacology research & perspectives vol. 5,2 (2017): e00301. doi: https://doi.org/10.1002/prp2.301
Fink BD, Guo DF, Kulkarni CA, Rahmouni K, Kerns RJ, Sivitz WI. Metabolic effects of a mitochondrial-targeted coenzyme Q analog in high fat fed obese mice. Pharmacol Res Perspect. 2017 Mar 10;5(2):e00301. doi: 10.1002/prp2.301. eCollection 2017 Apr. PMID: 28357127; PMCID: PMC5368965.
Copy Download .nbib Format: NLM
Evacetrapib: in vitro and clinical disposition, metabolism, excretion, and assessment of drug interaction potential with strong CYP3A and CYP2C8 inhibitors.

Pharmacology research & perspectives

Cannady EA, Wang MD, Friedrich S, Rehmel JL, Yi P, Small DS, Zhang W, Suico JG.
PMID: 26516590
Pharmacol Res Perspect. 2015 Oct;3(5):e00179. doi: 10.1002/prp2.179. Epub 2015 Oct 12.

Evacetrapib is an investigational cholesteryl ester transfer protein inhibitor (CETPi) for reduction of risk of major adverse cardiovascular events in patients with high-risk vascular disease. Understanding evacetrapib disposition, metabolism, and the potential for drug-drug interactions (DDI) may help guide...

Cite
Cannady EA, Wang MD, Friedrich S, et al. Evacetrapib: in vitro and clinical disposition, metabolism, excretion, and assessment of drug interaction potential with strong CYP3A and CYP2C8 inhibitors. Pharmacol Res Perspect. 2015;3(5):e00179doi: 10.1002/prp2.179.
Cannady, E. A., Wang, M. D., Friedrich, S., Rehmel, J. L., Yi, P., Small, D. S., Zhang, W., & Suico, J. G. (2015). Evacetrapib: in vitro and clinical disposition, metabolism, excretion, and assessment of drug interaction potential with strong CYP3A and CYP2C8 inhibitors. Pharmacology research & perspectives, 3(5), e00179. https://doi.org/10.1002/prp2.179
Cannady, Ellen A, et al. "Evacetrapib: in vitro and clinical disposition, metabolism, excretion, and assessment of drug interaction potential with strong CYP3A and CYP2C8 inhibitors." Pharmacology research & perspectives vol. 3,5 (2015): e00179. doi: https://doi.org/10.1002/prp2.179
Cannady EA, Wang MD, Friedrich S, Rehmel JL, Yi P, Small DS, Zhang W, Suico JG. Evacetrapib: in vitro and clinical disposition, metabolism, excretion, and assessment of drug interaction potential with strong CYP3A and CYP2C8 inhibitors. Pharmacol Res Perspect. 2015 Oct;3(5):e00179. doi: 10.1002/prp2.179. Epub 2015 Oct 12. PMID: 26516590; PMCID: PMC4618649.
Copy Download .nbib Format: NLM
Microparticle of drug and nanoparticle: a biosynthetic route.

Pharmacology research & perspectives

Sarkar S, Dasgupta AK.
PMID: 26516592
Pharmacol Res Perspect. 2015 Oct;3(5):e00188. doi: 10.1002/prp2.188. Epub 2015 Oct 02.

Microparticles (MPs) have great potentiality in material science- based applications. Their use in biology is however limited to clinics and has rarely been exploited in the pharmaceutical context. Unlike nanoparticles (NPs), they are amenable to routine detection by flow...

Cite
Sarkar S, Dasgupta AK. Microparticle of drug and nanoparticle: a biosynthetic route. Pharmacol Res Perspect. 2015;3(5):e00188doi: 10.1002/prp2.188.
Sarkar, S., & Dasgupta, A. K. (2015). Microparticle of drug and nanoparticle: a biosynthetic route. Pharmacology research & perspectives, 3(5), e00188. https://doi.org/10.1002/prp2.188
Sarkar, Sounik, and Dasgupta, Anjan Kr. "Microparticle of drug and nanoparticle: a biosynthetic route." Pharmacology research & perspectives vol. 3,5 (2015): e00188. doi: https://doi.org/10.1002/prp2.188
Sarkar S, Dasgupta AK. Microparticle of drug and nanoparticle: a biosynthetic route. Pharmacol Res Perspect. 2015 Oct;3(5):e00188. doi: 10.1002/prp2.188. Epub 2015 Oct 02. PMID: 26516592; PMCID: PMC4618651.
Copy Download .nbib Format: NLM
Acute cocaine exposure elicits rises in calcium in arousal-related laterodorsal tegmental neurons.

Pharmacology research & perspectives

Lambert MØ, Ipsen TH, Kohlmeier KA.
PMID: 28596834
Pharmacol Res Perspect. 2016 Dec 23;5(1):e00282. doi: 10.1002/prp2.282. eCollection 2017 Feb.

Cocaine has strong reinforcing properties, which underlie its high addiction potential. Reinforcement of use of addictive drugs is associated with rises in dopamine (DA) in mesoaccumbal circuitry. Excitatory afferent input to mesoaccumbal circuitry sources from the laterodorsal tegmental nucleus...

Cite
Lambert MØ, Ipsen TH, Kohlmeier KA. Acute cocaine exposure elicits rises in calcium in arousal-related laterodorsal tegmental neurons. Pharmacol Res Perspect. 2016;5(1):e00282doi: 10.1002/prp2.282.
Lambert, M. �. �., Ipsen, T. H., & Kohlmeier, K. A. (2017). Acute cocaine exposure elicits rises in calcium in arousal-related laterodorsal tegmental neurons. Pharmacology research & perspectives, 5(1), e00282. https://doi.org/10.1002/prp2.282
Lambert, Mads Ødum, et al. "Acute cocaine exposure elicits rises in calcium in arousal-related laterodorsal tegmental neurons." Pharmacology research & perspectives vol. 5,1 (2017): e00282. doi: https://doi.org/10.1002/prp2.282
Lambert MØ, Ipsen TH, Kohlmeier KA. Acute cocaine exposure elicits rises in calcium in arousal-related laterodorsal tegmental neurons. Pharmacol Res Perspect. 2016 Dec 23;5(1):e00282. doi: 10.1002/prp2.282. eCollection 2017 Feb. PMID: 28596834; PMCID: PMC5461641.
Copy Download .nbib Format: NLM
Structure-specific effects of lipidated oxytocin analogs on intracellular calcium levels, parental behavior, and oxytocin concentrations in the plasma and cerebrospinal fluid in mice.

Pharmacology research & perspectives

Cherepanov SM, Yokoyama S, Mizuno A, Ichinose W, Lopatina O, Shabalova AA, Salmina AB, Yamamoto Y, Okamoto H, Shuto S, Higashida H.
PMID: 28596839
Pharmacol Res Perspect. 2017 Jan 17;5(1):e00290. doi: 10.1002/prp2.290. eCollection 2017 Feb.

Oxytocin (OT) is a neuroendocrine nonapeptide that plays an important role in social memory and behavior. Nasal administration of OT has been shown to improve trust in healthy humans and social interaction in autistic subjects in some clinical trials....

Cite
Cherepanov SM, Yokoyama S, Mizuno A, et al. Structure-specific effects of lipidated oxytocin analogs on intracellular calcium levels, parental behavior, and oxytocin concentrations in the plasma and cerebrospinal fluid in mice. Pharmacol Res Perspect. 2017;5(1):e00290doi: 10.1002/prp2.290.
Cherepanov, S. M., Yokoyama, S., Mizuno, A., Ichinose, W., Lopatina, O., Shabalova, A. A., Salmina, A. B., Yamamoto, Y., Okamoto, H., Shuto, S., & Higashida, H. (2017). Structure-specific effects of lipidated oxytocin analogs on intracellular calcium levels, parental behavior, and oxytocin concentrations in the plasma and cerebrospinal fluid in mice. Pharmacology research & perspectives, 5(1), e00290. https://doi.org/10.1002/prp2.290
Cherepanov, Stanislav M, et al. "Structure-specific effects of lipidated oxytocin analogs on intracellular calcium levels, parental behavior, and oxytocin concentrations in the plasma and cerebrospinal fluid in mice." Pharmacology research & perspectives vol. 5,1 (2017): e00290. doi: https://doi.org/10.1002/prp2.290
Cherepanov SM, Yokoyama S, Mizuno A, Ichinose W, Lopatina O, Shabalova AA, Salmina AB, Yamamoto Y, Okamoto H, Shuto S, Higashida H. Structure-specific effects of lipidated oxytocin analogs on intracellular calcium levels, parental behavior, and oxytocin concentrations in the plasma and cerebrospinal fluid in mice. Pharmacol Res Perspect. 2017 Jan 17;5(1):e00290. doi: 10.1002/prp2.290. eCollection 2017 Feb. PMID: 28596839; PMCID: PMC5461640.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 1926 entries